Fintel reports that on July 1, 2024, ThinkEquity initiated coverage of BioVie (NasdaqCM:BIVI) with a Buy recommendation.
Analyst Price Forecast Suggests 1,859.18% Upside
As of February 24, 2024, the average one-year price target for BioVie is $8.16/share. The forecasts range from a low of $5.05 to a high of $11.55. The average price target represents an increase of 1,859.18% from its latest reported closing price of $0.42 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BioVie is 0MM. The projected annual non-GAAP EPS is -1.30.
What is the Fund Sentiment?
There are 104 funds or institutions reporting positions in BioVie. This is an decrease of 2 owner(s) or 1.89% in the last quarter. Average portfolio weight of all funds dedicated to BIVI is 0.01%, an increase of 1,506.82%. Total shares owned by institutions increased in the last three months by 247.28% to 6,853K shares. 
The put/call ratio of BIVI is 0.10, indicating a bullish outlook.
What are Other Shareholders Doing?
Altium Capital Management holds 3,013K shares representing 4.94% ownership of the company.
Sabby Management holds 689K shares representing 1.13% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Cvi Holdings holds 600K shares representing 0.98% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 415K shares representing 0.68% ownership of the company. In its prior filing, the firm reported owning 128K shares , representing an increase of 69.05%. The firm increased its portfolio allocation in BIVI by 23.56% over the last quarter.
Renaissance Technologies holds 347K shares representing 0.57% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
BioVie Background Information
(This description is provided by the company.)
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The Company has invented a patent-pending prefilled syringe that has been cleared for use in our upcoming Phase 2 trial subject to certain additional standard analytical tests. This novel BIV201 delivery system is expected to greatly simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. Room temperature stability has been achieved for 9 months providing an important advantage because, to the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration. The novel prefilled syringe format also avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution and improving sterility. BioVie has begun applying for global patent protection for this novel terlipressin delivery system. The Company has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
